Efficacy and Safety of Esketamine in Total Hip and Knee Arthroplasty: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
Cureus · 23.05.2026
DOI: 10.7759/cureus.109496 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Cureus, erschienen am 23.05.2026. Verfasst von Abdulrahman E AlAyyaf und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine and Surgery, Kuwait Institute for Medical Specialization, Kuwait City, KWT. Die Arbeit nennt 48 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
BACKGROUND: Total hip arthroplasty (THA) and total knee arthroplasty (TKA) are commonly performed procedures, but post-operative recovery is often complicated by significant pain, opioid-related side effects, and psychological distress. Esketamine has been proposed as an adjunct due to its analgesic and antidepressant properties, but its efficacy and safety remain unclear.
Methods
A systematic review and meta-analysis of randomized controlled trials (RCTs) was performed by searching PubMed, Scopus, Web of Science, and Cochrane Central Register of Controlled Trials (CENTRAL) up to July 2025. Dichotomous and continuous outcomes were synthesized using risk ratios (RRs) and standardized or mean differences, each reported with 95% confidence intervals (CIs).
Results
Seven RCTs involving 1,101 patients were included. Esketamine did not significantly reduce pain at rest at 12 or 24 hours. Low-certainty evidence suggested that esketamine may reduce pain during activity at 12 hours (standardized mean difference (SMD): -0.28; 95% CI: -0.45, -0.12; p < 0.001), although this effect was not sustained at 24 hours. Very low-certainty evidence suggested a possible reduction in anxiety scores at post-operative day 7, with no significant effect observed at day 1. No clear effect on depression was observed at any time point. Esketamine was associated with a higher incidence of hallucinations (RR: 4.36; 95% CI (1.48, 12.88); p = 0.01), with no significant differences in delirium, nightmares, or post-operative nausea and vomiting. CONCLUSIONS: Low- to very low-certainty evidence suggests that esketamine may provide modest short-term improvement in activity-related pain and delayed anxiety reduction following THA and TKA. However, findings should be interpreted cautiously given the limited number of studies, clinical heterogeneity, and instability observed in sensitivity analyses. Esketamine was also associated with an increased risk of hallucinations.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Medicine and Surgery, Kuwait Institute for Medical Specialization, Kuwait City, KWT.
- College of Medicine and Medical Sciences, Arabian Gulf University, Manama, BHR.
- Faculty of Medicine, University of Jordan, Amman, JOR.
- Department of Medicine and Surgery, Mubarak Al Kabeer Hospital, Kuwait City, KWT.
- Department of Orthopedics, Al-Razi Hospital, Kuwait City, KWT.
Zitieren
APA
AlAyyaf, A. E., Alharran, A. M., Al-Mutairi, M., Alazemi, W. B., Behbehani, M. A., Alajmi, M. M., Altamimi, K. M., Alqallaf, A., & Almohammad, A. Y. (2026). Efficacy and Safety of Esketamine in Total Hip and Knee Arthroplasty: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Cureus. https://doi.org/10.7759/cureus.109496
Vancouver
AlAyyaf AE, Alharran AM, Al-Mutairi M, Alazemi WB, Behbehani MA, Alajmi MM, et al. Efficacy and Safety of Esketamine in Total Hip and Knee Arthroplasty: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Cureus. 2026. doi:10.7759/cureus.109496
BibTeX
@article{AlAyyaf2026,
author = {AlAyyaf, Abdulrahman E and Alharran, Abdullah M and Al-Mutairi, Mohammad and Alazemi, Waleed B and Behbehani, Mohammad A and Alajmi, Mezna M and Altamimi, Khaled M and Alqallaf, Abdulmuhsen and Almohammad, Ahmad Y},
title = {Efficacy and Safety of Esketamine in Total Hip and Knee Arthroplasty: A Systematic Review and Meta-Analysis of Randomized Controlled Trials},
journal = {Cureus},
year = {2026},
doi = {10.7759/cureus.109496}
}
EUVIMED